Cargando…

Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence

BACKGROUND AND OBJECTIVE: Circadian rhythms may influence the pharmacokinetics of drugs. This study aimed to elucidate whether the pharmacokinetics of the orally administered drug sunitinib are subject to circadian variation. METHODS: We performed studies in male FVB-mice aged 8–12 weeks, treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kloth, Jacqueline S. L., Binkhorst, Lisette, de Wit, Annelieke S., de Bruijn, Peter, Hamberg, Paul, Lam, Mei H., Burger, Herman, Chaves, Ines, Wiemer, Erik A. C., van der Horst, Gijsbertus T. J., Mathijssen, Ron H. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513224/
https://www.ncbi.nlm.nih.gov/pubmed/25647628
http://dx.doi.org/10.1007/s40262-015-0239-5
_version_ 1782382611015925760
author Kloth, Jacqueline S. L.
Binkhorst, Lisette
de Wit, Annelieke S.
de Bruijn, Peter
Hamberg, Paul
Lam, Mei H.
Burger, Herman
Chaves, Ines
Wiemer, Erik A. C.
van der Horst, Gijsbertus T. J.
Mathijssen, Ron H. J.
author_facet Kloth, Jacqueline S. L.
Binkhorst, Lisette
de Wit, Annelieke S.
de Bruijn, Peter
Hamberg, Paul
Lam, Mei H.
Burger, Herman
Chaves, Ines
Wiemer, Erik A. C.
van der Horst, Gijsbertus T. J.
Mathijssen, Ron H. J.
author_sort Kloth, Jacqueline S. L.
collection PubMed
description BACKGROUND AND OBJECTIVE: Circadian rhythms may influence the pharmacokinetics of drugs. This study aimed to elucidate whether the pharmacokinetics of the orally administered drug sunitinib are subject to circadian variation. METHODS: We performed studies in male FVB-mice aged 8–12 weeks, treated with single-dose sunitinib at six dosing times. Plasma and tissue samples were obtained for pharmacokinetic analysis and to monitor messenger RNA (mRNA) expression of metabolizing enzymes and drug transporters. A prospective randomized crossover study was performed in which patients took sunitinib once daily at 8 a.m., 1 p.m., and 6 p.m at three subsequent courses. Patients were blindly randomized into two groups, which determined the sequence of the sunitinib dosing time. The primary endpoint in both studies was the difference in plasma area under the concentration–time curve (AUC) of sunitinib and its active metabolite SU12662 between dosing times. RESULTS: Sunitinib and SU12662 plasma AUC in mice followed an ~12-h rhythm as a function of administration time (p ≤ 0.04). The combined AUC from time zero to 10 h (AUC(10)) was 14–27 % higher when sunitinib was administered at 4 a.m. and 4 p.m. than at 8 a.m. and 8 p.m. Twenty-four-hour rhythms were seen in the mRNA levels of drug transporters and metabolizing enzymes. In 12 patients, sunitinib trough concentrations (C (trough)) were higher when the drug was taken at 1 p.m. or 6 p.m. than when taken at 8 a.m. (C (trough-1 p.m). 66.0 ng/mL; C (trough-6 p.m.) 58.9 ng/mL; C (trough-8 a.m.) 50.7 ng/mL; p = 0.006). The AUC was not significantly different between dosing times. CONCLUSIONS: Our results indicate that sunitinib pharmacokinetics follow an ~12-h rhythm in mice. In humans, morning dosing resulted in lower C (trough) values, probably resulting from differences in elimination. This can have implications for therapeutic drug monitoring. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40262-015-0239-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4513224
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-45132242015-07-24 Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence Kloth, Jacqueline S. L. Binkhorst, Lisette de Wit, Annelieke S. de Bruijn, Peter Hamberg, Paul Lam, Mei H. Burger, Herman Chaves, Ines Wiemer, Erik A. C. van der Horst, Gijsbertus T. J. Mathijssen, Ron H. J. Clin Pharmacokinet Original Research Article BACKGROUND AND OBJECTIVE: Circadian rhythms may influence the pharmacokinetics of drugs. This study aimed to elucidate whether the pharmacokinetics of the orally administered drug sunitinib are subject to circadian variation. METHODS: We performed studies in male FVB-mice aged 8–12 weeks, treated with single-dose sunitinib at six dosing times. Plasma and tissue samples were obtained for pharmacokinetic analysis and to monitor messenger RNA (mRNA) expression of metabolizing enzymes and drug transporters. A prospective randomized crossover study was performed in which patients took sunitinib once daily at 8 a.m., 1 p.m., and 6 p.m at three subsequent courses. Patients were blindly randomized into two groups, which determined the sequence of the sunitinib dosing time. The primary endpoint in both studies was the difference in plasma area under the concentration–time curve (AUC) of sunitinib and its active metabolite SU12662 between dosing times. RESULTS: Sunitinib and SU12662 plasma AUC in mice followed an ~12-h rhythm as a function of administration time (p ≤ 0.04). The combined AUC from time zero to 10 h (AUC(10)) was 14–27 % higher when sunitinib was administered at 4 a.m. and 4 p.m. than at 8 a.m. and 8 p.m. Twenty-four-hour rhythms were seen in the mRNA levels of drug transporters and metabolizing enzymes. In 12 patients, sunitinib trough concentrations (C (trough)) were higher when the drug was taken at 1 p.m. or 6 p.m. than when taken at 8 a.m. (C (trough-1 p.m). 66.0 ng/mL; C (trough-6 p.m.) 58.9 ng/mL; C (trough-8 a.m.) 50.7 ng/mL; p = 0.006). The AUC was not significantly different between dosing times. CONCLUSIONS: Our results indicate that sunitinib pharmacokinetics follow an ~12-h rhythm in mice. In humans, morning dosing resulted in lower C (trough) values, probably resulting from differences in elimination. This can have implications for therapeutic drug monitoring. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40262-015-0239-5) contains supplementary material, which is available to authorized users. Springer International Publishing 2015-02-03 2015 /pmc/articles/PMC4513224/ /pubmed/25647628 http://dx.doi.org/10.1007/s40262-015-0239-5 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Research Article
Kloth, Jacqueline S. L.
Binkhorst, Lisette
de Wit, Annelieke S.
de Bruijn, Peter
Hamberg, Paul
Lam, Mei H.
Burger, Herman
Chaves, Ines
Wiemer, Erik A. C.
van der Horst, Gijsbertus T. J.
Mathijssen, Ron H. J.
Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence
title Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence
title_full Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence
title_fullStr Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence
title_full_unstemmed Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence
title_short Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence
title_sort relationship between sunitinib pharmacokinetics and administration time: preclinical and clinical evidence
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513224/
https://www.ncbi.nlm.nih.gov/pubmed/25647628
http://dx.doi.org/10.1007/s40262-015-0239-5
work_keys_str_mv AT klothjacquelinesl relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence
AT binkhorstlisette relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence
AT dewitanneliekes relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence
AT debruijnpeter relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence
AT hambergpaul relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence
AT lammeih relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence
AT burgerherman relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence
AT chavesines relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence
AT wiemererikac relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence
AT vanderhorstgijsbertustj relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence
AT mathijssenronhj relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence